Insight journal - Therapy

Cardiovascular partnering – recent market research analysis 2009-2014

Posted on 23 September 2014

Tags: , , , ,

Recent market research analysis by Current Agreements shows that partnering in the last decade has seen an increase in cardiovascular deals with an increase in modern diagnostic technology development.

Cardiovascular disease is a class of disease that affects the heart and blood vessels (collectively the cardiac system).

According to the Current Agreements, cardiovascular partnering has been one of the most widely chosen therapeutic areas with more than 1000 partnering deals announced since 2009.

Cardiovascular deal making activity is commonly found among big pharma and biotech companies, smaller healthcare industries and academic institutions.

The data in this article has been sourced from the newly published Cardiovascular Partnering Terms and Agreements report

The following figure shows cardiovascular partnering frequency between 2009 and mid September 2014.

Figure 1: Cardiovascular partnering since 2009

c1

 

 

 

 

 

 

 

Source: Current Agreements, 2014

It is evident that partnering activity has been varied since 2009. As we enter into the month of September, this year has seen 108 cardiovascular partnering deals suggesting many more to come this year. On an average, 198 deals have been announced in the cardiovascular therapy area focus by life sciences industries.

According to Current Agreements, pharma and biotech companies are very active in cardiovascular deal making. However, pharmaceutical companies have been the most active in recent years collaborating with several big pharma companies in the development stage of compounds.

An example to cite would be the recent deal where Thoratec acquired Duraheart ventricular assist system from Terumo for a total of $56.5 million comprising upfront and milestone payments…click here for more on this deal.

The following figure provides an overview of cardiovascular partnering by major industry sector since 2009

Figure 2: Cardiovascular partnering by industry sector since 2009

c2

 

 

 

 

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2014

Analysis from our Current Agreements database, suggests that the vast majority of deals are made at the marketed stage showing promise in the disease treatment and more drugs in the market in this area.

Figure 3: Cardiovascular partnering by stage of development since 2009

c3

 

 

 

 

 

 

 

Source: Current Agreements, 2014

Cardiovascular, being an exciting and thriving area showing promise in better treatments can have a high headline deal value.

The following figure shows the leading cardiovascular deals by headline value of the deal when announced between 2009 and 2014.

 Figure 4: Top Cardiovascular deals by value since 2009

c4

 

 

 

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2014

Cardiovascular partnering is often targeted towards one of more specific cardiovascular indications. Some of the popular and commonly partnered cardiovascular therapeutics indications are congestive heart failure, coronary artery disease and hypertension. The following figure illustrates all the individual cardiovascular therapeutic indications recorded in our database.

Figure 5: Cardiovascular partnering by individual therapeutics area since 2009

c5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2014

Figure 6: Most active cardiovascular dealmakers

The following list provides an insight into the most active dealmakers in cardiovascular partnering between 2009 and mid September 2014.

c6

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2014

Details of the deals entered by these companies can be viewed in detail on subscription to our database Current Agreements.

The Cardiovascular Partnering Terms and Agreements report published by Current Partnering provides full details of over 1,000 cardiovascular deals announced since 2009 and includes average deal terms including headline, upfront, milestone and royalty rates, where available. In addition, the report provides details of deals broken down by deal type, stage of development, company A-Z, specific individual therapy area and technology type. More details here

Sources

The above information has been abstracted from the following resources:

Shamini Thiagarajan

 

Related

Read: more cardiovascular deals in pharma, biotech, life science partnering deal news, insights and glossary

Report:Cardiovascular Partnering Terms and Agreements

View also:Other specific cardiovascular indication reports

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering Insight Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma partnering activity – latest trends in big pharma deal making activity

View: Current Partnering’s Big biotech partnering activity – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on:LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

 

Print Friendly, PDF & Email

Leave a Reply